CAS: 67165-56-4; 4-(3,4-Dichlorophenyl)-7-Methoxy-2-Methyl-1,2,3,4-Tetrahydroisoquinoline

上下游产品

CAS号802051-24-7 3,4-Dichloro-α-...

📜N-甲基-3-甲氧基苄胺置于sodium Tetrahydroborate,硫酸体系中,用 甲醇,二氯甲烷,水 作为反应溶剂,化学反应 32.0H,反应生成 (+/-)-双氮奋兴
参考文献: Aryl,Heteroaryl,And Heterocycle Substituted Tetrahydroisoquinolines And Use Thereof[fr] Aryle,Hétéroaryle Et Tétrahydroisoquinolines à Hétérocycle Substitué Et Leur Utilisation
标题: Aryl,Heteroaryl,And Heterocycle Substituted Tetrahydroisoquinolines And Use Thereof[fr] Aryle,Hétéroaryle Et Tétrahydroisoquinolines à Hétérocycle Substitué Et Leur Utilisation
摘要:本发明描述了新颖的芳基,杂芳基和非芳香杂环取代的四氢异喹啉化合物.这些化合物用于治疗各种神经和生理疾病.本发明还描述了制备这些化合物的方法.

专利信息

专利号:WO-2008084057-A1
优先权日:2007-01-10
标题:Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
发明人：LANGE JOSEPHUS H M; KRUSE CORNELIS G
权利人:SOLVAY PHARM BV; LANGE JOSEPHUS H M; KRUSE CORNELIS G
摘要:This invention relates to compounds with a combination of cannabinoid-CB1antagonism and serotonin reuptake inhibition to pharmaceutical compositions containing these compounds, to methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders. In particular the invention relates to compoundsof the general formula (I): wherein the symbols have the meanings given in the specification.

专利号:US-8138174-B2
优先权日:2007-01-10
标 题:Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
发明人：LANGE JOSEPHUS H M; KRUSE CORNELIS G
权利人:LANGE JOSEPHUS H M; KRUSE CORNELIS G; SOLVAY PHARM BV
摘要:Compounds with a combination of cannabinoid CB 1 antagonism and serotonin reuptake inhibition, pharmaceutical compositions containing these compounds, methods for preparing these compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing these compositions are disclosed. Uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders are disclosed. n In at least one embodiment, the invention relates to compounds of the general formula (1): n nwherein the substitutents have the definitions given in the specification.